An observational study in Central Nervous System Neoplasm, Leptomeningeal Neoplasm and Metastatic Malignant Neoplasm in the Brain, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by M.D. Anderson Cancer Center · Observational
This study evaluates patient perceptions around quality of care through telemedicine in neuro-oncology. Studying questionnaires related to perceptions quality of care through telemedicine in patients with brain cancer may help doctors to improve the delivery of care through this modality.
PRIMARY OBJECTIVE:
I. To evaluate the patient-perceived quality of care by group (telemedicine versus in-person visits) in patients with central nervous system (CNS) cancer.
SECONDARY OBJECTIVES:
I. To characterize the visits provided by telemedicine compared to those in-person.
II. To contrast the average time spent on telemedicine visits compared to in-person visits, and the delay between visit order placement and visit occurring.
III. To evaluate the domains of patient care addressed on a telemedicine visit versus in-person visit per documentation, including (1) treatment planning, (2) symptom burden, (3) goals of care.
IV. To evaluate frequency of acute care sought (through emergency room or urgent care clinic) within 30 days of encounter in telemedicine visit versus (vs) in-person visit.
V. The impact of patient and clinical characteristics on perceived quality of care in the context of covariate-adjusted modeling.
OUTLINE:
Patients complete a survey related to their perceived quality of care via telephone and have their medical chart reviewed prospectively.
699 studies on the registry are indexed under Central Nervous System Neoplasms; 66 are open to participants now.
This study's planned enrollment of 200 is above the median of 118 across 90 observational studies indexed under Central Nervous System Neoplasms.
Browse Central Nervous System Neoplasms studies →M.D. Anderson Cancer Center is the lead sponsor of 3,047 studies on the registry; 578 are open to participants now.
Of its 612 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with encounters at the Brain and Spine Center between 4/20/2020 and either (1) 8/30/2020 or (2) date that the state of emergency secondary to the COVID-19 pandemic is declared terminated in the United States of America- whichever date is earlier
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Established patients with a follow up encounter with Neuro-Oncology at the Brain and Spine Center at the University of Texas MD Anderson Cancer Center; this encounter can be
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients complete a survey related to their perceived quality of care via telephone and have their medical chart reviewed prospectively.
Other: Electronic Health Record Review · Other: Survey Administration
Review of medical chart
Complete survey
Survey response to question 6 of the quality of care survey ("I felt I received good medical care during this encounter")
Survey responses will be summarized by ordinal category as counts with percentages, separately by group. Will separately estimate the proportion of each ordinal level of each group with 95% confidence interval.
Time frame: through study completion, an average of 1 year
Quality of Care Survey
Will separately estimate the proportion of each ordinal level of each group with 95% confidence interval.
Time frame: through study completion, an average of 1 year
Patients and clinical characteristics
Differences between groups will be assessed by 2-sample 2-sided t-test and Mann-Whitney test, Fisher's exact test, or chi-square test.
Time frame: Baseline
Interactive time spent during visit
Will be summarized by group per mean, median, standard deviation, and range. Differences between groups will be assessed by t-test and Mann-Whitney test.
Time frame: through study completion, an average of 1 year
Time from visit order placement to visit occurring
Will be summarized by group per mean, median, standard deviation, and range. Differences between groups will be assessed by t-test and Mann-Whitney test.
Time frame: through study completion, an average of 1 year
Domains of patient care addressed during a visit, including treatment planning, symptom burden, and goals of care
Will be summarized as counts with percentages by group. Differences between groups will be assessed by chi-square test.
Time frame: through study completion, an average of 1 year
Incidence of acute care sought (through emergency room or urgent care clinic)
Will be summarized as counts with percentages by group. Differences between groups will be provisionally assessed by Fisher's exact test.
Time frame: Within 30 days of encounter
Started Aug 2020 (actual). Primary completion is estimated for Dec 2026, 76 months after the start.
Of 39 observational studies under Central Nervous System Neoplasms, half reached primary completion within 92 months of starting (the median), counting those still running; a quarter within 41. This study's planned 76 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Nervous System Neoplasms →